<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Clin Epigenetics</journal-id>
<journal-id journal-id-type="iso-abbrev">Clin Epigenetics</journal-id>
<journal-title-group>
<journal-title>Clinical Epigenetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1868-7075</issn>
<issn pub-type="epub">1868-7083</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31685013</article-id>
<article-id pub-id-type="pmc">6830011</article-id>
<article-id pub-id-type="publisher-id">749</article-id>
<article-id pub-id-type="doi">10.1186/s13148-019-0749-3</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A genome-wide DNA methylation signature for <italic>SETD1B</italic>-related syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Krzyzewska</surname>
<given-names>I. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Maas</surname>
<given-names>S. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Henneman</surname>
<given-names>P.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lip</surname>
<given-names>K. v. d.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Venema</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baranano</surname>
<given-names>K.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chassevent</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aref-Eshghi</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author" deceased="yes">
<name>
<surname>van Essen</surname>
<given-names>A. J.</given-names>
</name>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fukuda</surname>
<given-names>T.</given-names>
</name>
<xref ref-type="aff" rid="Aff6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ikeda</surname>
<given-names>H.</given-names>
</name>
<xref ref-type="aff" rid="Aff7">7</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jacquemont</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="Aff8">8</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>H.-G.</given-names>
</name>
<xref ref-type="aff" rid="Aff9">9</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Labalme</surname>
<given-names>A.</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lewis</surname>
<given-names>S. M. E.</given-names>
</name>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lesca</surname>
<given-names>G.</given-names>
</name>
<xref ref-type="aff" rid="Aff10">10</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Madrigal</surname>
<given-names>I.</given-names>
</name>
<xref ref-type="aff" rid="Aff12">12</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mahida</surname>
<given-names>S.</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Matsumoto</surname>
<given-names>N.</given-names>
</name>
<xref ref-type="aff" rid="Aff13">13</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rabionet</surname>
<given-names>R.</given-names>
</name>
<xref ref-type="aff" rid="Aff14">14</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rajcan-Separovic</surname>
<given-names>E.</given-names>
</name>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qiao</surname>
<given-names>Y.</given-names>
</name>
<xref ref-type="aff" rid="Aff11">11</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sadikovic</surname>
<given-names>B.</given-names>
</name>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Saitsu</surname>
<given-names>H.</given-names>
</name>
<xref ref-type="aff" rid="Aff15">15</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sweetser</surname>
<given-names>D. A.</given-names>
</name>
<xref ref-type="aff" rid="Aff16">16</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Alders</surname>
<given-names>M.</given-names>
</name>
<address>
<email>m.alders@amsterdamumc.nl</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Mannens</surname>
<given-names>M. M. A. M.</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution>Amsterdam UMC, Department of Clinical Genetics, Genome Diagnostics laboratory Amsterdam, Reproduction &amp; Development, </institution><institution>University of Amsterdam, </institution></institution-wrap>Meibergdreef 9, Amsterdam, The Netherlands </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000084992262</institution-id><institution-id institution-id-type="GRID">grid.7177.6</institution-id><institution>Amsterdam UMC, Department of Pediatrics, </institution><institution>University of Amsterdam, </institution></institution-wrap>Meibergdreef 9, Amsterdam, The Netherlands </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0427 667X</institution-id><institution-id institution-id-type="GRID">grid.240023.7</institution-id><institution>Kennedy Krieger Institute, Department of Neurogenetics, </institution></institution-wrap>801 N. Broadway, Rm 564, Baltimore, MD 21205 USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1936 8884</institution-id><institution-id institution-id-type="GRID">grid.39381.30</institution-id><institution>Department of Pathology and Laboratory Medicine, </institution><institution>Western University, </institution></institution-wrap>800 Commissioner’s Road E, London, ON N6A 5W9 Canada </aff>
<aff id="Aff5"><label>5</label>University Medical Centre Groningen, University of Groningen, Department of Medical Genetics, Hanzeplein 1, 9713 GZ Groningen, The Netherlands </aff>
<aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.505613.4</institution-id><institution>Department of Pediatrics, </institution><institution>Hamamatsu University School of Medicine, </institution></institution-wrap>1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192 Japan </aff>
<aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0618 9684</institution-id><institution-id institution-id-type="GRID">grid.419174.e</institution-id><institution>National Epilepsy Centre, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, </institution></institution-wrap>886 Urushiyama, Aoi-ku, Shizuoka 420-8688 Japan </aff>
<aff id="Aff8"><label>8</label>Department of medical genetics, CHU La Reunion-Groupe Hospitalier Sud Reunion, La Reunion, France </aff>
<aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1789 3191</institution-id><institution-id institution-id-type="GRID">grid.452146.0</institution-id><institution>Neurological Disorder Center Qatar Biomedical Research Institute, </institution><institution>Hamad Bin Khalifa University, </institution></institution-wrap>Doha, Qatar </aff>
<aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2163 3825</institution-id><institution-id institution-id-type="GRID">grid.413852.9</institution-id><institution>Department of medical genetics, </institution><institution>Hospices Civils de Lyon, </institution></institution-wrap>Bron, France </aff>
<aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="GRID">grid.413941.a</institution-id><institution>Department of Medical Genetics, </institution><institution>Children’s &amp; Women’s Health Centre of British Columbia University of British Columbia, </institution></institution-wrap>C234-4500 Oak Street, Vancouver, British Columbia V6H 3N1 Canada </aff>
<aff id="Aff12"><label>12</label>Biochemistry and Molecular Genetics Service, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Center for Biomedical Network Research on Rare Diseases (CIBERER), Barcelona, Spain </aff>
<aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 1033 6139</institution-id><institution-id institution-id-type="GRID">grid.268441.d</institution-id><institution>Department of Human Genetics, Graduate School of Medicine, </institution><institution>Yokohama City University, </institution></institution-wrap>Fukuura 3-9, Kanazawa-ku, Yokohama, 236-0004 Japan </aff>
<aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 1937 0247</institution-id><institution-id institution-id-type="GRID">grid.5841.8</institution-id><institution>Department of Genetics, Microbiology and Statistics, Faculty of Biology, </institution><institution>University of Barcelona, </institution></institution-wrap>av diagonal 643, 08028 Barcelona, Spain </aff>
<aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="GRID">grid.505613.4</institution-id><institution>Department of Biochemistry, </institution><institution>Hamamatsu University School of Medicine, </institution></institution-wrap>1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192 Japan </aff>
<aff id="Aff16"><label>16</label>MassGeneral Hospital, Division of Medical Genetics and Metabolism, 175 Cambridge St, Suite 500, Boston, Massachusetts 02114 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>4</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>4</day>
<month>11</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>11</volume>
<elocation-id>156</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>7</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2019</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p id="Par1">SETD1B is a component of a histone methyltransferase complex that specifically methylates Lys-4 of histone H3 (H3K4) and is responsible for the epigenetic control of chromatin structure and gene expression. De novo microdeletions encompassing this gene as well as de novo missense mutations were previously linked to syndromic intellectual disability (ID). Here, we identify a specific hypermethylation signature associated with loss of function mutations in the <italic>SETD1B</italic> gene which may be used as an epigenetic marker supporting the diagnosis of syndromic <italic>SETD1B</italic>-related diseases. We demonstrate the clinical utility of this unique epi-signature by reclassifying previously identified <italic>SETD1B</italic> VUS (variant of uncertain significance) in two patients.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>
<institution>Catalan Government PERIS program SLT002/16/00310</institution>
</funding-source>
</award-group>
</funding-group>
<funding-group>
<award-group>
<funding-source>
<institution>Techgene project from the FP7 framework ID: 223143</institution>
</funding-source>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Introduction</title>
<p id="Par15">Currently, five patients have been described with a microdeletion 12q31.24 and comparable phenotypes [<xref ref-type="bibr" rid="CR1">1</xref>–<xref ref-type="bibr" rid="CR5">5</xref>]. The lost fragment of chromosome 12 varied in size and included multiple genes. Labonne et al. [<xref ref-type="bibr" rid="CR5">5</xref>] identified the smallest overlapping region and proposed two histone modifiers, <italic>KDM2B</italic> and <italic>SETD1B</italic>, as the most probable candidates to be responsible for the microdeletion 12q24.31 syndrome. <italic>SETD1B</italic> encodes a SET domain-containing protein, which is a part of a histone methyltransferase complex. The key role of this complex is methylation of histone 3 on lysine 4 (H3K4), which is enriched in gene promoters and is seen to be highly correlated to gene expression [<xref ref-type="bibr" rid="CR6">6</xref>]. <italic>KDM2B</italic> is a member of the F-protein family and encodes an enzyme that demethylates H3K36me2/3 and H3K4me3 [<xref ref-type="bibr" rid="CR7">7</xref>]. Labonne et al. [<xref ref-type="bibr" rid="CR5">5</xref>] showed that the genetic organization of 12q24.31 is conserved between zebrafish and humans and that <italic>KDM2B</italic> and <italic>SETD1B</italic> were expressed in the brain tissue of both zebrafish and human, suggesting evolutionary conservation of the regulation of these genes [<xref ref-type="bibr" rid="CR5">5</xref>]. More recently, three patients with de novo point mutations in <italic>SETD1B</italic> have been described [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Their phenotypes were similar to patients with a 12q24.31 microdeletion.</p>
<p id="Par16">Since it has been shown that there is a strong relationship between the methylation of H3K4 and DNA methylation [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR13">13</xref>], we set out to determine whether the <italic>SETD1B</italic> and <italic>KDM2B</italic> aberrations can manifest with a specific DNA methylation signature. For this, a genome wide-methylation analysis was performed on DNA samples from 13 patients with either aberrations of 12q24 (including or not including <italic>KDM2B</italic> and/or <italic>SETD1B</italic> genes) or mutations in <italic>SETD1B</italic> (Table <xref ref-type="table" rid="Tab1">1</xref>). This set of patients included previously described patients and additional cases identified in our laboratory or through GeneMatcher [<xref ref-type="bibr" rid="CR14">14</xref>].
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Cohort—molecular characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Patient no.</th><th>Patient ID</th><th>Aberrations</th><th>Pathogenicity</th><th>Inheritance</th><th>SETD1B aberrations/variations</th><th>KDM2B aberration</th><th><italic>SETD1B</italic> DNAm signature</th><th>Batch</th><th>Previously reported</th></tr></thead><tbody><tr><td>1</td><td>1_mut</td><td>p.Arg1301*</td><td>Pathogenic</td><td>de novo</td><td>Yes</td><td>No</td><td>
<italic>Yes</italic>
</td><td>1</td><td>No;</td></tr><tr><td>2</td><td>2_mut</td><td>p.Arg1902Cys</td><td>Pathogenic</td><td>de novo</td><td>Yes</td><td>No</td><td>
<italic>Yes</italic>
</td><td>1</td><td>No</td></tr><tr><td>3</td><td>3_mut</td><td>p.Arg1902Cys</td><td>Pathogenic</td><td>de novo</td><td>Yes</td><td>No</td><td>
<italic>Yes</italic>
</td><td>2</td><td>Yes; Hiraide et al. [<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td>4</td><td>4_mut</td><td>p.Arg1885Trp</td><td>Pathogenic</td><td>de novo</td><td>Yes</td><td>No</td><td>
<italic>Yes</italic>
</td><td>2</td><td>Yes; Hiraide et al. [<xref ref-type="bibr" rid="CR8">8</xref>]</td></tr><tr><td>5</td><td>5_mut</td><td>p.Arg1885Trp</td><td>Pathogenic</td><td>unknown</td><td>Yes</td><td>No</td><td>
<italic>Yes</italic>
</td><td>2</td><td>No</td></tr><tr><td>6</td><td>6_mut</td><td>p.Glu1692del</td><td>VUS</td><td>unknown</td><td>Yes</td><td>No</td><td>No</td><td>1</td><td>No</td></tr><tr><td>7</td><td>7_mut</td><td>p.Glu1160Lys</td><td>VUS</td><td>de novo</td><td>Yes</td><td>No</td><td>No</td><td>2</td><td>No</td></tr><tr><td rowspan="4">8</td><td rowspan="4">1_del12q</td><td>The minimal deletion:</td><td rowspan="4">VUS</td><td rowspan="4">Pat. inheritance</td><td rowspan="4">No</td><td rowspan="4">Yes</td><td rowspan="4">No</td><td rowspan="4">1</td><td rowspan="4">Yes; Chouery et al. [<xref ref-type="bibr" rid="CR2">2</xref>]</td></tr><tr><td>12q24.3(121150820-122120257)</td></tr><tr><td>The maximal deletion:</td></tr><tr><td>12q24.3(121139660-122135589)</td></tr><tr><td rowspan="4">9</td><td rowspan="4">2_del12q</td><td>The minimal deletion:</td><td rowspan="4">Pathogenic</td><td rowspan="4">de novo</td><td rowspan="4">Yes</td><td rowspan="4">Yes</td><td rowspan="4">
<italic>Yes</italic>
</td><td rowspan="4">2</td><td rowspan="4">No</td></tr><tr><td>12q24.31(121838818-122405204)</td></tr><tr><td>The maximal deletion:</td></tr><tr><td>12q24.31(121814901-122423659)</td></tr><tr><td rowspan="4">10</td><td rowspan="4">3_del12q</td><td>The minimal deletion:</td><td rowspan="4">Pathogenic</td><td rowspan="4">de novo</td><td rowspan="4">Yes</td><td rowspan="4">Yes</td><td rowspan="4">
<italic>Yes</italic>
</td><td rowspan="4">1</td><td rowspan="4">Yes; Labonne et al. [<xref ref-type="bibr" rid="CR5">5</xref>]</td></tr><tr><td>12q24.31(121895610-122271171)</td></tr><tr><td>The maximal deletion:</td></tr><tr><td>12q24.31(121882128-122294222)</td></tr><tr><td rowspan="4">11</td><td rowspan="4">4_del12q</td><td>The minimal deletion:</td><td rowspan="4">Pathogenic</td><td rowspan="4">de novo</td><td rowspan="4">Yes</td><td rowspan="4">No</td><td rowspan="4">
<italic>Yes</italic>
</td><td rowspan="4">1</td><td rowspan="4">Yes; Qiao et al. [<xref ref-type="bibr" rid="CR4">4</xref>]</td></tr><tr><td>12q24.31(122255880-123758046)</td></tr><tr><td>The maximal deletion:</td></tr><tr><td>12q24.31(122234178-123780094)</td></tr><tr><td rowspan="4">12</td><td rowspan="4">5_del12q</td><td>The minimal deletion:</td><td rowspan="4">VUS</td><td rowspan="4">unknown</td><td rowspan="4">No</td><td rowspan="4">No</td><td rowspan="4">No</td><td rowspan="4">2</td><td rowspan="4">No</td></tr><tr><td>12q24.31q-12q24.32(122844745-127838399)</td></tr><tr><td>The maximal deletion:</td></tr><tr><td>12q24.31q-12q24.32(12:122825331-127854607)</td></tr><tr><td rowspan="2">13</td><td rowspan="2">dup12q</td><td>The minimal duplication:</td><td rowspan="2">VUS</td><td rowspan="2">Mat. inheritance</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">No</td><td rowspan="2">1</td><td rowspan="2">No</td></tr><tr><td>12q24.12(12:112169989-112313658)</td></tr></tbody></table><table-wrap-foot><p>*Mutations are reported according to NM_001353345.1; Hg19</p><p>The minimal deletion/duplication within the given start and end position</p><p>The maximal deletion—without the given start and end position (between)</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec2">
<title>Results</title>
<sec id="Sec3">
<title>Identification of <italic>a SETD1B</italic>-related specific methylation signature</title>
<p id="Par17">Genomic DNA was obtained from whole blood samples (13 patients and 60 controls), and genome methylation status was analyzed using the Infinium MethylationEPIC BeadChip. The determination of DNAm signature based on HumanMethylation array was previously validated and described in various studies [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR19">19</xref>].</p>
<p id="Par18">The principal component analysis (PCA) of the data obtained showed two outliers in our cohort: a patient with a microdeletion including <italic>SETD1B</italic> and <italic>KDM2B</italic> (3_del12q; Batch1) and a healthy control (4 days old, batch 2). Estimation of the blood cell types in patient 3_del12q showed an unexpected distribution of cell types (99% of B lymphocytes). Both outliers were excluded from further group analysis. Quality control (QC) of the data, PCA analysis, and estimation of the blood cell type distribution are described in detail in the supplemental information and listed in Additional file <xref ref-type="media" rid="MOESM1">1</xref>: Table S1.</p>
<p id="Par19">Next, a group-based differential methylation analysis was carried out, comparing the DNAm of five patients with pathogenic variants in <italic>SETD1B</italic> to that in controls (<italic>n</italic> = 59). Variants were considered pathogenic if the following was observed: (<italic>i</italic>) variants were de novo and occurred in more than one patient or (<italic>ii</italic>) variants resulted in a premature stop codon. The patients included in the group analysis were patient 1_mut (p.Arg1301*), patients 2_mut and 3_mut (p.Arg1902Cys), and patients 4_mut and 5_mut (p.Arg1885Trp).</p>
<p id="Par20">A shift of the genome-wide methylation toward hypermethylation was observed (Fig. <xref ref-type="fig" rid="Fig1">1</xref>), which is reflected in the selected significant differentially methylated CpGs (adj. P-value_M &lt; 0.05, absolute beta difference &gt; 0.1). This analysis identified 3340 significant differentially methylated CpGs, out of which more than 82% had a positive beta difference. All significant differentially methylated CpGs identified in this analysis are listed in Additional file <xref ref-type="media" rid="MOESM2">2</xref>: Table S2. To further calculate the probability that we would have identified that these 3340 CpGs as significant by chance, we performed an additional permutation analysis on the group labels. 99.6% of 3340 significant differentially methylated CpGs displayed <italic>P</italic> value less than or equal to 0.05. Details of this analysis are described in the additional information and listed in the Additional file <xref ref-type="media" rid="MOESM6">6</xref>: Table S6.
<fig id="Fig1"><label>Fig. 1</label><caption><p>The volcano plot of the methylation difference between patients with certain pathogenic variation in <italic>SETD1B</italic> and healthy individuals (group analysis). The <italic>y</italic>-axis represents a negative log<sub>10</sub> of adj. <italic>P</italic>-values_M; the <italic>x</italic>-axis represents the different beta values between patients and controls. Each dot on the plot represents a single CpG site. The horizontal, dotted line represents the statistical significance threshold (adj. <italic>P</italic>-values_M = 0.05). The vertical, dotted lines show the effect-size threshold (− 0.1 and 0.1). CpGs with adj. P-value_M lesser than 0.05 and an absolute beta difference higher than 0.1 are highlighted in green</p></caption><graphic id="MO1" xlink:href="13148_2019_749_Fig1_HTML"></graphic></fig></p>
<p id="Par21">Next, unsupervised hierarchical clustering of beta values of the identified significant CpG sites (3340 CpGs) for each individual of our cohort was created; 13 patients and 60 controls (Fig. <xref ref-type="fig" rid="Fig2">2</xref>). Eight of the 13 patients were clustered in a separate group. All five patients with pathogenic variants in <italic>SETD1B</italic> (patients included in the “<italic>SETD1B</italic>-related” group analysis); two patients with a deletion including <italic>KDM2B</italic> and <italic>SETD1B</italic> (2_del12q, 3_del12q) and one with a deletion including only <italic>SETD1B</italic> (4_del12q) fell into this cluster. Note that although patient 3_del12q had an aberrant blood cell composition, the methylation signature was detectable in this sample. These results demonstrate the robustness of the specific DNAm of the <italic>SETD1B</italic> aberrations/variations. Despite the many variables in the cohort that may have had an impact on the DNAm (different ethnicity, different aberrations/variations, a different method of DNA isolation small sample size, batch, age, and distribution of the cell types), there is a distinct <italic>SETD1B</italic> specific methylation signature. The methylation profile of the patients with a deletion excluding <italic>SETD1B</italic> (1_del12q and 5_del12q_a), a patient that carried a duplication of the 12q region, and two patients with a variant of uncertain significance, in <italic>SETD1B</italic> (6_mut and 7_mut), did not show the <italic>SETD1B-</italic>specific signature.
<fig id="Fig2"><label>Fig. 2</label><caption><p><italic>SETD1B</italic>-related DNAm signature<bold>.</bold> Unsupervised hierarchical clustering of 3340 CpG sites identified in the <italic>SETD1B</italic> group analysis (DNAm of patients with certain pathogenic aberration/variation in <italic>SETD1B</italic> compared to that in healthy controls). C represents controls; aberrations/variations are annotated to patients. Note that the data was obtained from two batches</p></caption><graphic id="MO2" xlink:href="13148_2019_749_Fig2_HTML"></graphic></fig></p>
</sec>
<sec id="Sec4">
<title>Examination of the specificity of the <italic>SETD1B</italic>-related DNAm signature</title>
<p id="Par22">We examined whether the DNA methylation signature of <italic>SETD1B</italic>-related syndrome overlaps with that of other neurodevelopmental disorders or syndromes, which in some cases, are caused by mutations in the members of the epigenetic machinery. Using a multidimensional scaling of the methylation values across the CpGs differentially methylated in the <italic>SETD1B</italic>-related syndrome, we examined the methylation profile of a total of 502 individuals with a confirmed diagnosis of various syndromes with previously described epi-signatures including imprinting defect disorders [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR20">20</xref>] (Angelman syndrome, Prader–Willi syndrome, Silver–Russell syndrome, and Beckwith–Wiedemann syndrome), BAFopathies (Coffin-Siris and Nicolaides-Baraitser syndromes), Autosomal dominant cerebellar ataxia, deafness, and narcolepsy, Floating–Harbor syndrome, Cornelia de Lang syndrome, Claes–Jensen syndrome, ADNP syndrome, ATRX syndrome, Kabuki syndrome, CHARGE syndrome, Fragile X syndrome, trisomy 21, Williams syndrome, and Chr7 duplication syndrome (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). All of these patients showed a DNA methylation pattern different from the <italic>SETD1B</italic>-related syndrome and were clustered with controls, indicating that the identified epi-signature is highly specific to <italic>SETD1B</italic> loss of function.
<fig id="Fig3"><label>Fig. 3</label><caption><p>Multidimensional scaling (MDS) of 502 individuals with neurodevelopmental disorders. Red dots represent eight patients with <italic>SETD1B</italic>-related DNAm signature of the current study, blue dots represent controls of the current study, and green dots represent patients with other disorders</p></caption><graphic id="MO3" xlink:href="13148_2019_749_Fig3_HTML"></graphic></fig></p>
</sec>
<sec id="Sec5">
<title>Identification of the <italic>SETD1B</italic>-related differentially methylated regions</title>
<p id="Par23">Using the “bumphunte<italic>r”</italic> R-package, four genomic regions differentially methylated between patients with pathogenic variants in <italic>SETD1B</italic> (as defined above) and controls were identified (minimum three differentially methylated CpGs in a region; family-wise error rate (Fwer) &lt; 0.05) (Table <xref ref-type="table" rid="Tab2">2</xref>). All four regions were hypermethylated in patients and located in the regulatory clusters of active promoters, enhancers, and DNAse hypersensitivity (UCSC Genome Browser on Human; GRCh37/hg19 [<xref ref-type="bibr" rid="CR21">21</xref>]), three of which were annotated to genes <italic>(i) KLHL28, FAM179B; (ii) RUNX1;</italic> and <italic>(iii) BRD2.</italic>
<table-wrap id="Tab2"><label>Table 2</label><caption><p>DMRs identified in the group analysis of certain pathogenic aberrations/variants in SETD1B</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Chr</th><th>Start</th><th>End</th><th>Value</th><th>L</th><th>ClusterL</th><th>Fwer</th><th>Gene_Name</th></tr></thead><tbody><tr><td>chr6</td><td>26195488</td><td>26195995</td><td>0,45</td><td>5</td><td>5</td><td>0,002</td><td></td></tr><tr><td>chr14</td><td>45431885</td><td>45432516</td><td>0,40</td><td>4</td><td>21</td><td>0,014</td><td>
<italic>KLHL28;FAM179B</italic>
</td></tr><tr><td>chr21</td><td>36258423</td><td>36259797</td><td>0,21</td><td>13</td><td>13</td><td>0,02</td><td>
<italic>RUNX1</italic>
</td></tr><tr><td>chr6</td><td>32942063</td><td>32943025</td><td>0,26</td><td>11</td><td>128</td><td>0,026</td><td>
<italic>BRD2</italic>
</td></tr></tbody></table><table-wrap-foot><p>Value –represents the difference between patient end controls</p><p><italic>L</italic>– number of differentially methylated CpGs in the detected region, <italic>Cluster L</italic>– number of CpGs in the genomic cluster, <italic>Fwer</italic>– family-wise error rate</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec6">
<title>Analysis of the genomic distribution of the CpG sites in the <italic>SETD1B</italic> DNAm signature</title>
<p id="Par24">An analysis of the genomic distribution of the CpG sites identified in the group analysis was conducted. This showed an over-representation of CpGs in the gene body, DNase hypersensitivity sites (DHS), CpG island S-shore, reprogramming differentially methylated regions (RDMR), and in promoter-associated sites (Fig. <xref ref-type="fig" rid="Fig4">4</xref>). These results demonstrate that the disrupted methylation related to the <italic>SETD1B</italic> function is enriched in the regulatory parts of the genome.
<fig id="Fig4"><label>Fig. 4</label><caption><p>Genomic distribution of the significant differentially methylated CpG sites identified in group analysis according to the genomic annotations of the epic array. The light blue bars (EPIC) represent all the informative probes included in the data (777,148 CpGs) and the dark blue bars the CpGs identified in the group analysis (TOP; 3340 CpGs). The numbers on the top of the bars represent the percentage distribution of CpGs for each category. All categories are listed in the supplemental information—Infinium Methylation EPIC Manifest Column Headings®. This comparison demonstrates the enrichment in the body (between the ATG and stop codon), DHS–DNase I hypersensitivity site, RDMR–reprogramming-specific differentially methylated region, promoter-associated, and promoter-associated cell-type specific</p></caption><graphic id="MO4" xlink:href="13148_2019_749_Fig4_HTML"></graphic></fig></p>
</sec>
<sec id="Sec7">
<title>Over-representation analysis (ORA) of CPGs in the <italic>SETD1B</italic> DNAm signature</title>
<p id="Par25">To identify the processes involved in the development of the phenotype, ORA analysis based on gene names associated with the 3340 identified significant methylated CpGs using WEB-based GEne SeT AnaLysis Toolkit [<xref ref-type="bibr" rid="CR22">22</xref>] was performed. The analysis for biological processes displayed enrichment for genes with a function in chromosome organization, regulation of organelle organization, cell cycle, and regulation of cell death. ORA for molecular function demonstrates enrichment for genes with a role in the regulation of gene activity, such as RNA binding, protein domain-specific binding, regulatory region nucleic acid binding, and transcription regulatory region DNA binding. ORA for the human phenotype (top 10 highest ranked features) showed enrichment in genes related to facial and posture abnormalities. The results of ORA are summarized in Table <xref ref-type="table" rid="Tab3">3</xref>. Note that ORA analysis is very general and the results should be interpreted with caution.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of the ORA</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="8">Gene ontology: biological processes</th></tr><tr><th></th><th>Description</th><th>
<italic>C</italic>
</th><th>
<italic>O</italic>
</th><th>
<italic>E</italic>
</th><th>
<italic>R</italic>
</th><th>pValue</th><th>FDR</th></tr></thead><tbody><tr><td>GO:0051276</td><td>Chromosome organization</td><td>1143</td><td>165</td><td>97.67</td><td>1.69</td><td>5.59E−12</td><td>5.08E−08</td></tr><tr><td>GO:0033043</td><td>Regulation of organelle organization</td><td>1245</td><td>175</td><td>106.39</td><td>1.64</td><td>1.16E−11</td><td>5.26E−08</td></tr><tr><td>GO:0007049</td><td>Cell cycle</td><td>1739</td><td>223</td><td>148.60</td><td>1.50</td><td>1.15E−10</td><td>3.48E−07</td></tr><tr><td>GO:0006915</td><td>Apoptotic process</td><td>1911</td><td>239</td><td>163.30</td><td>1.46</td><td>2.52E−10</td><td>5.74E−07</td></tr><tr><td>GO:0010941</td><td>Regulation of cell death</td><td>1648</td><td>210</td><td>140.83</td><td>1.49</td><td>7.83E−10</td><td>1.42E−06</td></tr><tr><td>GO:0006325</td><td>Chromatin organization</td><td>741</td><td>112</td><td>63.32</td><td>1.77</td><td>1.35E−09</td><td>1.90E−06</td></tr><tr><td>GO:0033554</td><td>Cellular response to stress</td><td>1867</td><td>231</td><td>159.54</td><td>1.45</td><td>1.47E−09</td><td>1.90E−06</td></tr><tr><td>GO:0010942</td><td>Positive regulation of cell death</td><td>660</td><td>102</td><td>56.40</td><td>1.81</td><td>2.28E−09</td><td>2.60E−06</td></tr><tr><td>GO:0010629</td><td>Negative regulation of gene expression</td><td>1733</td><td>216</td><td>148.09</td><td>1.46</td><td>3.00E−09</td><td>2.87E−06</td></tr><tr><td>GO:0034613</td><td>Cellular protein localization</td><td>1815</td><td>224</td><td>155.10</td><td>1.44</td><td>3.44E−09</td><td>2.87E−06</td></tr><tr><td colspan="8">Gene ontology: molecular function</td></tr><tr><td> GO:0003723</td><td>RNA binding</td><td>1603</td><td>203</td><td>131.47</td><td>1.54</td><td>7.52E−11</td><td>8.28E−08</td></tr><tr><td> GO:0019904</td><td>Protein domain specific binding</td><td>684</td><td>106</td><td>56.10</td><td>1.89</td><td>8.82E−11</td><td>8.28E−08</td></tr><tr><td> GO:0001067</td><td>Regulatory region nucleic acid binding</td><td>898</td><td>129</td><td>73.65</td><td>1.75</td><td>1.39E−10</td><td>8.70E−08</td></tr><tr><td> GO:0044212</td><td>Transcription regulatory region DNA binding</td><td>896</td><td>128</td><td>73.48</td><td>1.74</td><td>2.38E−10</td><td>1.12E−07</td></tr><tr><td> GO:0043565</td><td>Sequence-specific DNA binding</td><td>1097</td><td>146</td><td>89.97</td><td>1.62</td><td>1.87E−09</td><td>7.02E−07</td></tr><tr><td> GO:0003690</td><td>Double-stranded DNA binding</td><td>915</td><td>126</td><td>75.04</td><td>1.68</td><td>3.41E−09</td><td>1.07E−06</td></tr><tr><td> GO:0000976</td><td>Transcription regulatory region sequence-specific DNA binding</td><td>781</td><td>111</td><td>64.05</td><td>1.73</td><td>5.41E−09</td><td>1.45E−06</td></tr><tr><td> GO:1990837</td><td>Sequence-specific double-stranded DNA binding</td><td>823</td><td>115</td><td>67.50</td><td>1.70</td><td>7.55E−09</td><td>1.77E−06</td></tr><tr><td> GO:0000977</td><td>RNA polymerase II regulatory region sequence-specific DNA binding</td><td>729</td><td>103</td><td>59.79</td><td>1.72</td><td>2.69E−08</td><td>5.62E−06</td></tr><tr><td> GO:0001012</td><td>RNA polymerase II regulatory region DNA binding</td><td>735</td><td>103</td><td>60.28</td><td>1.71</td><td>4.11E−08</td><td>7.72E−06</td></tr><tr><td colspan="8">Human Phenotype Ontology</td></tr><tr><td> HP:0002346</td><td>Head tremor</td><td>20</td><td>10</td><td>1.87</td><td>5.36</td><td>3.48E−06</td><td>0.016253</td></tr><tr><td> HP:0011337</td><td>Abnormality of mouth size</td><td>269</td><td>43</td><td>25.09</td><td>1.71</td><td>2.13E−04</td><td>0.167774</td></tr><tr><td> HP:0004097</td><td>Deviation of finger</td><td>320</td><td>49</td><td>29.85</td><td>1.64</td><td>2.23E−04</td><td>0.167774</td></tr><tr><td> HP:0000311</td><td>Round face</td><td>73</td><td>17</td><td>6.81</td><td>2.50</td><td>2.80E−04</td><td>0.167774</td></tr><tr><td> HP:0000219</td><td>Thin upper lip vermilion</td><td>137</td><td>26</td><td>12.78</td><td>2.03</td><td>2.84E−04</td><td>0.167774</td></tr><tr><td> HP:0011228</td><td>Horizontal eyebrow</td><td>8</td><td>5</td><td>0.75</td><td>6.70</td><td>3.04E−04</td><td>0.167774</td></tr><tr><td> HP:0005306</td><td>Capillary hemangioma</td><td>26</td><td>9</td><td>2.43</td><td>3.71</td><td>3.59E−04</td><td>0.167774</td></tr><tr><td> HP:0001894</td><td>Thrombocytosis</td><td>21</td><td>8</td><td>1.96</td><td>4.08</td><td>3.63E−04</td><td>0.167774</td></tr><tr><td> HP:0100559</td><td>Lower limb asymmetry</td><td>21</td><td>8</td><td>1.96</td><td>4.08</td><td>3.63E−04</td><td>0.167774</td></tr><tr><td> HP:0000107</td><td>Renal cyst</td><td>203</td><td>34</td><td>18.93</td><td>1.80</td><td>4.21E−04</td><td>0.167774</td></tr></tbody></table><table-wrap-foot><p><italic>C</italic> reference genes in the category, <italic>O</italic> observed number of genes in the category, <italic>E</italic> expected number of genes in the category, <italic>R</italic> ratio of enrichment, <italic>pValue p</italic> value from hypergeometric test, <italic>FDR</italic> false discovery rate</p></table-wrap-foot></table-wrap></p>
</sec>
<sec id="Sec8">
<title>Analysis of a <italic>KDM2B</italic>-related specific methylation signature</title>
<p id="Par26">Only three patients in this cohort had a deletion of <italic>KDM2B</italic> (1_del12q, 2_del12q, 3_del12q), one of whom presented with a deletion excluding <italic>SETD1B</italic> (1_del12q). Furthermore, of these, patient 3_del12q was excluded from the group analysis due to the heavily disturbed blood cell-type distribution. Despite these limitations, an attempt was made to identify a <italic>KDM2B</italic>-specific signature, running the group analysis of only two patients (1_del12q, 2_del12q) compared to 59 controls. This identified 697 significant differently methylated CpG sites (adj. <italic>P</italic>-value_M &lt; 0.05 and absolute beta difference &gt; 0.1). Nevertheless, the unsupervised hierarchical clustering (Fig. <xref ref-type="fig" rid="Fig5">5</xref>) of the 697 identified CpGs did not show any specific methylation signature related to <italic>KDM2B.</italic> The two patients (1_del12q and 2_del12q) were clustered separately from each other, other patients, and healthy controls. Moreover, the <italic>SETD1B</italic>-related specific signature was still strongly marked. All significant differentially methylated CpGs identified in this analysis are listed in Additional file <xref ref-type="media" rid="MOESM3">3</xref>: Table S3.
<fig id="Fig5"><label>Fig. 5</label><caption><p>Unsuperviesed hierarchical clustering of the 697 CpG sites identified in KDM2B group analysis. C–represents controls, aberrations/variations annotated to patients. The data was obtained from two batches</p></caption><graphic id="MO5" xlink:href="13148_2019_749_Fig5_HTML"></graphic></fig></p>
</sec>
<sec id="Sec9">
<title>Identification of the <italic>KDM2B</italic>-related differentially methylated regions</title>
<p id="Par27">The DMR analysis did not show any significant DMR (minimum of three differentially methylated CpGs in a region; Fwer &lt; 0.05).</p>
</sec>
<sec id="Sec10">
<title>Clinical features</title>
<p id="Par28">All patients with a <italic>SETD1B</italic> signature-positive methylation profile presented with an intellectual disability. Common features included language delay, epilepsy, and behavioral problems such as autism spectrum disorder and anxiety. Dysmorphisms included full cheeks, full lower lip, macroglossia, and tapering fingers. Delay in motor development was primarily present in patients with a deletion and absent in patients with a point mutation in <italic>SETD1B</italic> (Table <xref ref-type="table" rid="Tab4">4</xref>).
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Summary of clinical features of patients with variation/aberration within the <italic>SETD1B</italic> gene</p></caption><table frame="hsides" rules="groups"><thead><tr><th></th><th colspan="8">Specific SETD1B-related DNAm signature (this study)</th><th colspan="2">Other previously reported patients (not included in this study)</th><th colspan="2">Non-SETD1B DNAm signature</th></tr><tr><th>Clinical features</th><th>mut_1<break></break>Male<break></break>13 years<break></break>Disrupted SETD1B</th><th>mut_2<break></break>Male<break></break>16 years<break></break>Disrupted SETD1B</th><th>3_mut<break></break>Male<break></break>34 years<break></break>Disrupted SETD1B</th><th>4_mut<break></break>Female<break></break>12 years<break></break>Disrupted SETD1B</th><th>5_mut<break></break>Male<break></break>7 years<break></break>Disrupted SETD1B</th><th>2_del12q<break></break>Female<break></break>12 years<break></break>Disrupted SETD1B and KDM2B</th><th>3_del12q<break></break>Male<break></break>3 years<break></break>Disrupted SETD1B and KDM2B</th><th>4_del12q<break></break>Female<break></break>16 years<break></break>Disrupted SETD1B</th><th>Baple et al. [<xref ref-type="bibr" rid="CR1">1</xref>]<break></break>Female<break></break>11 years<break></break>Disrupted SETD1B and KDM2B</th><th>Palumbo et al. [<xref ref-type="bibr" rid="CR3">3</xref>]<break></break>Female<break></break>11 years<break></break>Disrupted SETD1B and KDM2B</th><th>6_mut<break></break>Male<break></break>8 years<break></break>VUS SETD1B</th><th>7_mut<break></break>Male<break></break>10 years<break></break>VUS SETD1B</th></tr></thead><tbody><tr><td colspan="13">Growth parameters at birth</td></tr><tr><td> Height</td><td>48 cm</td><td>NA</td><td>NA</td><td>–</td><td><p>47 cm</p><p>(5th centile)</p></td><td><p>52 cm</p><p>(+ 0.45 SD)</p></td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td> Weight</td><td>2.9 kg</td><td><p>2.52 kg</p><p>(2.5 SD)</p></td><td><p>3.6 kg</p><p>(+ 1.5 SD)</p></td><td><p>3.55 kg</p><p>(+ 1.4 SD)</p><p>34.5 cm</p><p>(+ 1.1 SD)</p></td><td><p>2.8 kg</p><p>(9th centile)</p></td><td><p>3.78 kg</p><p>(+ 1.45 SD)</p></td><td>NA</td><td>NA</td><td>4094 g (90–95th centile)</td><td>2650 g (5–10th centile)</td><td>3260.2 (25–50th centile)</td><td>NA</td></tr><tr><td> Head circumference</td><td>33 cm</td><td>NA</td><td>NA</td><td>NA</td><td><p>33 cm</p><p>(10th centile)</p></td><td><p>35 cm</p><p>(− 0.1 SD)</p></td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td></tr><tr><td colspan="13">Growth parameters at last evaluation</td></tr><tr><td> Height</td><td>167.5 cm (at 30 years)</td><td>193 cm (+ 1.45SD)</td><td>NA</td><td>NA</td><td>1.35 m (+ 1.8 SD)</td><td>170 cm (+ 1.2SD) (at 13)</td><td>NA</td><td>(98th centile)</td><td>157.5 cm (98th centile)</td><td>(10–25th centile)</td><td>13 cm (67th centile)</td><td>NA</td></tr><tr><td> Weight</td><td>111.8 kg (at 30 years)</td><td>67 kg (− 0.15SD)</td><td>NA</td><td>NA</td><td>46 kg (&gt;&gt; + 3 SD)</td><td>84.9 kg; + 2.5 SD (according to height)</td><td>NA</td><td>(98th centile)</td><td>91.5 kg (98–99,6th centile)</td><td>(10–25th centile)</td><td>46.8 kg (95th centile)</td><td></td></tr><tr><td> Head circumference</td><td>60 cm (at 30 years)</td><td>NA</td><td>NA</td><td>NA</td><td>51 cm (− 1.2 SD)</td><td>48 cm; − 0.97 SD at 3 years</td><td>NA</td><td>(98th centile)</td><td>54.8 cm (75th centile)</td><td>(10–25th centile)</td><td>54 cm</td><td>NA</td></tr><tr><td colspan="13">Dysmorphisms</td></tr><tr><td> Head</td><td>–</td><td>NA</td><td>NA</td><td>Normal</td><td>NA</td><td>Prominent forehead</td><td>Narrow face, prominent forehead, plagiocephaly</td><td>NA</td><td>NA</td><td>NA</td><td>Very fair hair</td><td>NA</td></tr><tr><td> Eye</td><td>–</td><td>Up slant palpebral fissures, proptosis</td><td>Thick eye brows</td><td>Normal</td><td>Thick eyebrows, hypertelorism, sunken eyes, short palpebral fissures</td><td>Telecanthu, epicanthus</td><td>Hypertelorism</td><td>Up slanting palpebral fissures, synophrys</td><td>NA</td><td>NA</td><td>Very Fair (blue)</td><td>Upslant palpebral fissures, myopia</td></tr><tr><td> Ear</td><td>–</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Thick helix</td><td>Tags preauriculair</td><td>Folded ear ridges</td><td>Small, low set and posteriorly rotated</td><td>Large, narrow with thick helix and rotated</td><td>Large and narrow with a thick helix</td><td>NA</td><td>NA</td></tr><tr><td> Nose</td><td>–</td><td>Asymmetric due to cleft lip</td><td>Normal</td><td>Normal</td><td>Normal</td><td>Short upturned nose, large nose bridge</td><td>NA</td><td>Height nasal bridge, square tip</td><td>Broad nasal based</td><td>Broad base; high root</td><td>NA</td><td>NA</td></tr><tr><td> Cheeks</td><td>Full</td><td>Normal</td><td>Full</td><td>Normal</td><td>Full</td><td>Full</td><td>NA</td><td>NA</td><td>Full</td><td>Full</td><td>NA</td><td>NA</td></tr><tr><td> Lip</td><td>–</td><td>Cleft lip</td><td>Full lower lip</td><td>Normal</td><td>Full</td><td>Full lower lip; short philtrum</td><td>NA</td><td>NA</td><td>Full and everted lower lip</td><td>Full and everted lower lip</td><td>NA</td><td>Malformation of upper lip, prominent upper lip</td></tr><tr><td> Mouth</td><td>–</td><td>Cleft jaw bilateral</td><td>NA</td><td>Normal</td><td>NA</td><td>Macroglossia; prognathic</td><td>NA</td><td>Minor micrognathia</td><td>Macroglossia</td><td>Macroglossia</td><td>NA</td><td>NA</td></tr><tr><td> Palate</td><td>–</td><td>Cleft palate</td><td>NA</td><td>Normal</td><td>NA</td><td>NA</td><td>NA</td><td>Narrow palate</td><td>High arch</td><td>High arch</td><td>NA</td><td>NA</td></tr><tr><td> Teeth</td><td>–</td><td>Misaligned due to cleft jaw</td><td>NA</td><td>Normal</td><td>Oligodontia</td><td>Irregular, oligodontia</td><td>NA</td><td>Prominent front incisors</td><td>Overcrowded</td><td>Overcrowded</td><td>NA</td><td>Malaligned teeth with increased spacing</td></tr><tr><td colspan="13">Developmental delay</td></tr><tr><td> Intellectual disability</td><td>Mild – moderate</td><td>Mild</td><td>Profound</td><td>Mild</td><td>Profound</td><td>+</td><td></td><td>Moderate</td><td>Moderate</td><td>moderate to severe</td><td>mild-to-moderate</td><td>+</td></tr><tr><td> Motor development</td><td>Walk without support</td><td>–</td><td>Walk without support</td><td>Walk without support</td><td>Walk without support</td><td>Normally but her movements are not fluent</td><td>+</td><td>Global developmental delay</td><td>Walk with a broad-based gait</td><td>global developmental delay</td><td>global developmental delay</td><td>+</td></tr><tr><td> Language delay</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+; few words at 2 years old</td><td>–</td><td>first words at 3 years</td><td>NA</td></tr><tr><td> Anxiety</td><td>–</td><td>–</td><td>+</td><td>–</td><td></td><td></td><td>+</td><td>–</td><td>+</td><td>+</td><td>–</td><td>NA</td></tr><tr><td>Autism/autistic behavior</td><td>–</td><td>–</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>–</td><td>+; at 4 years</td><td>+</td><td>–</td><td>+</td></tr><tr><td colspan="13">Epilepsy/seizures/spasms</td></tr><tr><td> Type</td><td>Frontal-temporal</td><td>In early childhood absences, alter tonic-clonic seizures</td><td>Myoclonic seizures (3y11m)</td><td>Myoclonic seizures (2y9m),</td><td>NA</td><td>NA</td><td>Myoclonic seizures</td><td>NA</td><td>–</td><td>Tonic-clonic seizures</td><td>No seizures</td><td>Tonic-clonic seizures remotely in childhood and more recently complex partial seizures</td></tr><tr><td>Fingers abnormality</td><td>NA</td><td>Fetal pads</td><td>Tapering fingers- mild</td><td>–</td><td>Tapering fingers-mild</td><td>Clinodactyly</td><td>Tapering fingers</td><td>Tapering fingers with prominent fingertip pads</td><td><p>Tapering finger – mild left</p><p>4th finger proximally implanted</p></td><td>Tapering fingers – mild</td><td>–</td><td>Long fingers, widened tips, 5th finger clinodactyly</td></tr><tr><td>Toes</td><td>Foot pronation</td><td>Normal</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>NA</td><td>Bilateral hypo-plastic nails on both halluces</td><td>Short toes</td><td>NA</td><td>–</td><td>NA</td></tr><tr><td>Hypoglycemia</td><td>–</td><td>–</td><td>–</td><td>–</td><td>NA</td><td>–</td><td>NA</td><td>NA</td><td>+</td><td>+</td><td>–</td><td>NA</td></tr><tr><td>Hypotonia</td><td>+</td><td>–</td><td>–</td><td>–</td><td>NA</td><td>–</td><td>+</td><td>–</td><td>+</td><td>–</td><td>–</td><td>NA</td></tr><tr><td>Additional findings</td><td>Obsessive interest for electronic objects and their accumulation, acute pancreatitis, cholecystectomy, liver steatosis</td><td></td><td></td><td></td><td>Urinary continence problems</td><td>Umbilical hernia at birth, hyperactivity - PDD NOS/ADHD; obstipation</td><td></td><td>T cell skin lymphoma on the lower back; hypo-plastic nails, patchy eczema, thick ichthyic skin</td><td>Cafe-au-lait spot:1 truncal; large hands and feet; urinary continence problems inverted nipples;</td><td></td><td>His skin is also very fair</td><td>Cerebral visual impairment; ptosis</td></tr></tbody></table><table-wrap-foot><p><italic>NA</italic> not available, “+” feature present, “-” feature absent</p></table-wrap-foot></table-wrap></p>
</sec>
</sec>
<sec id="Sec11">
<title>Discussion</title>
<p id="Par29">Pathogenic changes within the <italic>SETD1B</italic> gene were found to have an associated specific DNAm signature. This specific DNAm was not substantially affected by differences in blood cell distribution and other variables such as technical differences and chromosomal aberrations. The specificity of the DNAm signature was highlighted by the lack of signature in patients carrying a deletion that did not include <italic>SETD1B</italic> or in a patient carrying a duplication of the region or patients with other neurodevelopmental disorders or syndromes. Moreover, we were able to assess the pathogenicity of two variants of unknown clinical significance: p.(Glu1692del) and p.(Glu1160Lys) in patients 6_mut and 7_mut, respectively.</p>
<p id="Par30">The inheritance of variant p.(Glu1692del) in patient 6_mut was unknown. This variant results in the loss of residue Glu1692. The p.(Glu1160Lys) variant in the 7_mut patient occurred de novo<italic>.</italic> It is a missense variant present at very low frequencies in the general population (5/187386 alleles in the GnomAD database [<xref ref-type="bibr" rid="CR23">23</xref>]; MAF &lt; 0.01; rs959370052) and affects a weakly conserved amino acid. The methylation profile of both patients did not display a specific <italic>SETD1B</italic> signature, suggesting both variants do not result in a loss of <italic>SETD1B</italic> function and are probably not pathogenic. While patients 6_mut and 7_mut display clinical features compatible with the phenotype caused by <italic>SETD1B</italic> mutations, this is not related to the specific <italic>SETD1B</italic> methylation pattern, indicating that they do not have a <italic>SETD1B</italic>-related disorder.</p>
<p id="Par31">We detected the specific <italic>SETD1B</italic>-related DNAm signature based on the methylation status of three different pathogenic variants in five patients. An increased sample size would lead to the possibility of detecting differences in DNAm between variants.</p>
<p id="Par32">Four hypermethylated DMRs were found to be associated with <italic>SETD1B.</italic> The region located on chromosome 6 (chr6: 26195488-26195995; hg19) was not assigned to any gene and was found to be characterized by high DNase hypersensitivity with promoter activity and located in <italic>Homo sapiens</italic> histone cluster 1. Histone 1 (H1) is responsible for chromatin condensation and DNA fragmentation during apoptosis [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Note that the apoptotic process, regulation of cell death, and chromatin condensation were enriched in ORA (biological processes) of CpG sites of the <italic>SETD1B</italic>-related DNAm-specific signature. Another hypermethylated region on chromosome 6 (chr6: 32942063-32943025; hg19) was assigned to the <italic>BRD2</italic> gene. It displays promoter and enhancer activity and overlaps exon 3 of <italic>BRD2.</italic> Pathak et al. [<xref ref-type="bibr" rid="CR26">26</xref>] reported hypermethylation in another locus (CPG75) near the promoter of <italic>BRD2</italic> as implicated in juvenile myoclonic epilepsy (JME) [<xref ref-type="bibr" rid="CR26">26</xref>]. Hypermethylation of this locus was found to be associated with a single nucleotide polymorphism (rs3918149). Schultz et al. [<xref ref-type="bibr" rid="CR27">27</xref>] could not confirm this association in the German population. However, in 2007, Cavalleri et al. published the results of genotyping rs3918149 variant across five independent JME cohorts, observing a significant effect of this SNP on epilepsy in the British and the Irish cohorts, but not in those of the German, Australian, and Indian [<xref ref-type="bibr" rid="CR28">28</xref>]. Although the association of <italic>BRD2</italic> and epilepsy is not clear, we tentatively speculate that the hypermethylation detected in <italic>BRD2</italic> in our cohort may play a role in the occurrence of epilepsy in these patients. Two other hypermethylated DMRs detected in the <italic>SETD1B</italic>-related group analysis were found to be located on chromosomes 14 and 21 (chr14:45431885-45432516; chr21:36258423-36259797; hg19) and assigned to genes <italic>KLHL28</italic>, <italic>FAM179B</italic>, and <italic>RUNX1</italic>. The former covers a CpG island with promoter activity and a DNAse hypersensitivity cluster (exon 1 of <italic>FAM179B</italic>) while the latter corresponds to a CpG island with promoter activity at exon 4 of <italic>RUNX1</italic> and a DNAse hypersensitivity cluster. The biological function of these genes could not be related to clinical features in our cohort; however, their localization in genomic regulatory regions suggests a role in <italic>SETD1B-</italic>related disorders.</p>
<p id="Par33">A comparison of phenotypes of patients with a <italic>SETD1B</italic> DNAm signature showed overlapping clinical features such as intellectual disability, language delay, autism, seizures, full cheeks, and tapering fingers (Table <xref ref-type="table" rid="Tab4">4</xref>). Interestingly, two patients presenting with the microdeletion, involving also <italic>KDM2B</italic>, were initially diagnosed with Beckwith Wiedemann syndrome (BWS) because of overgrowth and macroglossia, which are typical for BWS (MIM 130650). Hiraide et al. (2018) suggested that the deletion of <italic>KDM2B</italic> could be a possible reason for an overgrowth phenotype in these two patients [<xref ref-type="bibr" rid="CR8">8</xref>]. Moreover, a <italic>KDM2B</italic> missense mutation (c.2503G &gt; A) was identified to be associated with “paunch calf syndrome” [<xref ref-type="bibr" rid="CR29">29</xref>]. The characteristic features of this syndrome include abdominal distension and tongue protrusion that are comparable with abdominal wall defects and macroglossia, features that are characteristics for BWS [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
<p id="Par34">The results of this study show a strong effect of <italic>SETD1B</italic> function on DNA methylation<italic>. SETD1B</italic> is a known histone modifier that produces trimethylated histone H3 at Lys4 (H3K4me3), which may play a role in blocking of the de novo DNA methylation in some genomic regions. DNMT3L ((cytosine-5)-methyltransferase 3-like), which stimulates de novo DNA methylation, interacts only with unmodified H3K4. The methylation of H3K4 disables this interaction [<xref ref-type="bibr" rid="CR31">31</xref>]. The loss of the function of <italic>SETD1B</italic> may lead to the insufficient production of H3K4me3 and, thereby, hypermethylation of the DNA in specific loci. Indeed, 82% of differentially methylated CpGs in patients with a <italic>SETD1B</italic> pathogenic variant were hypermethylated. The 18% of differentially methylated CpGs that were hypomethylated remain unexplained by this mechanism, but these may be secondary effects, caused by altered expression of target genes of <italic>SETD1B.</italic></p>
<p id="Par35">Syndromic disorders have often similar clinical features. Genetic testing has multiple limitations. For instance, the resolution often prevents it from detecting low-frequency mosaicism. Moreover, the reason underlying the clinical features can occasionally not easily be inferred from the variants if variant occurs in non-coding regions, contiguous genes are deleted, or if they have been annotated as VUS. Examination of specific DNAm signatures was previously described as a powerful solution in the classification of various unresolved cases including syndromic Mendelian disorders, imprinting disorders, repeat expansion disorders, and uncertain clinical diagnosis with VUS [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] and has therefore been proposed as a novel molecular diagnostic test. Our results reinforce this observation indicating that the specific DNAm signature has a diagnostic value and can be used as an additional diagnostic test to resolve variants of unknown significance in <italic>SETD1B</italic>.</p>
<p id="Par36">Due to the small sample, we were unable to determine whether the loss of the <italic>KDM2B</italic> caused a specific DNAm signature. Studies including a sufficient number of patients are needed to solve this. The other limitation of our study was the technical differences between samples. Different DNA isolation methods between samples may influence the results.</p>
</sec>
<sec id="Sec12">
<title>Methods</title>
<sec id="Sec13">
<title>Patients</title>
<p id="Par37">Whole blood DNA samples from 13 individuals were collected for the methylation study. Seven patients had point mutations in <italic>SETD1B</italic>, which were identified by whole-exome sequencing (WES), and five chromosomal 12q24.12-32 aberrations. One of the five patients had the deletion involving <italic>KDM2B</italic> (1_del12q), two the deletion of both <italic>KDM2B</italic> and <italic>SETD1B</italic> (2-del12q, 3_del12q), one the deletion on <italic>SETD1B</italic> (4_del12q), one the deletion not involving <italic>KDM2B</italic> and <italic>SETD1B</italic>, and one the duplication of 12q24.12 not involving <italic>KDM2B</italic> and <italic>SETD1B</italic>. Table <xref ref-type="table" rid="Tab1">1</xref> shows the genetic aberrations and inheritance of the patients included in the analysis. Figure <xref ref-type="fig" rid="Fig6">6</xref> depicts the comparison between the deleted regions and genes in patients with microdeletions of 12q24.31 from the cohort (according to Hg19). Informed consent was obtained for each patient.
<fig id="Fig6"><label>Fig. 6</label><caption><p>Comparison between deleted regions in patients with a microdeletion of 12q24.31. The light blue bars represent the deleted regions for individual patients. Numbers 1, 2, 3, 4, and 5 represent patients 1_del12q24.31, 2_del12q24.31, 3_del12q24.31, 4_del12q24.31, and 5_del12q24.31, respectively. The red frames highlight genes <italic>SETD1B</italic> and <italic>KDM2B</italic>. Note: microdeletion of patient 5_del12q24.31 has not been fully displayed on the plot and does not overlap <italic>KDM2B</italic> and <italic>SETD1B</italic></p></caption><graphic id="MO6" xlink:href="13148_2019_749_Fig6_HTML"></graphic></fig></p>
</sec>
<sec id="Sec14">
<title>Healthy controls</title>
<p id="Par38">Whole blood DNA samples were collected from 60 healthy individuals.</p>
<p id="Par39">Cohort details are listed in Additional file <xref ref-type="media" rid="MOESM4">4</xref>: Table S4.</p>
</sec>
<sec id="Sec15">
<title>Methylation EPIC array</title>
<p id="Par40">The samples were divided into two batches: the first contained seven DNA samples from the patients (two females and five males) and 40 samples from the healthy controls (20 females and 20 males) and the second contained six DNA samples from the patients (two females and four males) and 20 from the healthy controls (ten females and ten males). The samples were randomized and sent to GenomeScan in Leiden (ISO/IEC 17025 approved), where the bisulfite treatment and the hybridization to the Infinium Methylation EPIC array (Illumina) were processed. The raw methylation data were obtained and the quality (QC) of the data assessed using the MethylAid script in R. (GenomeScan’s Guidelines for Successful Methylation Experiments Using the Illumina Infinium® HumanMethylation BeadChip).</p>
</sec>
<sec id="Sec16">
<title>Normalization and data analysis</title>
<p id="Par41">The EPIC array data was loaded onto the R software and normalized using the <italic>preprocessFunnorm</italic> function of “minfi” R package [<xref ref-type="bibr" rid="CR32">32</xref>]. All probes containing SNPs (MAF &gt; 0.01), cross-hybridization probes, and probes located on the sex chromosomes were excluded; 776,920 probes remained for analysis. The beta values (ratio of the methylated probe intensity ranging from 0 to 1) were obtained for all the patients from the cohort. Row beta values were normalized and PCA carried out.</p>
</sec>
<sec id="Sec17">
<title>Estimation of the blood cell type distribution</title>
<p id="Par42">White blood cell type was estimated for each patient using <italic>estimateCellCounts</italic> function in R “FlowSorted.Blood.EPIC” package [<xref ref-type="bibr" rid="CR33">33</xref>]. The counts were calculated for CD8T (cytotoxische T cell), CD4T(T helper cells), NK (natural killer cells), B cell (B lymphocytes), mono (monocytes), and gran (granulocytes). The <italic>P</italic> value was calculated for each patient of our cohort (13 patients), for each cell type (Crawford-Howell <italic>t</italic> test; R software). Subsequently, the Bonferroni correction was applied for 78 tests (six cell types × 13 patients). We assume that the distribution of the cell types was significantly disturbed if the Bonferroni-corrected <italic>P</italic> value for the cell types was less than 0.05.</p>
</sec>
<sec id="Sec18">
<title>Group analysis and identification of CpG sites for the DNAm-specific signature</title>
<p id="Par43">DNA methylation of patients in the groups (five patients in the <italic>SETD1B</italic>-related group and two in the <italic>KDM2B</italic>-related group) were compared with methylation in a group of 59 healthy controls using the “minfi” R-package. The design model was corrected for age, gender, batch, and cell distribution. The beta values were obtained and logit transformed into <italic>M</italic> values. The adjusted <italic>P</italic> values for the <italic>M</italic> values were calculated, and the significance threshold was 0.05. Finally, to avoid false-positive results, CpG sites with an effect size of at least 10% difference in an average of DNAm between patient groups and the control group were selected. In this way, we identified 3340 and 697 differentially methylated CpGs in the <italic>SETD1B</italic>-related group and <italic>KDM2B</italic>-related group, respectively.</p>
</sec>
<sec id="Sec19">
<title>Analysis of a specific methylation signature</title>
<p id="Par44">Beta values of CpGs selected in the group analyses were used to perform the unsupervised hierarchical clustering (“pheatmap” R-package). Two heatmaps were created, one for the <italic>SETD1B</italic>-related group and the other for the <italic>KDM2B</italic>-related group. Each heatmap was created for all individuals in the cohort (13 patients and 60 controls).</p>
</sec>
<sec id="Sec20">
<title>Examination of the specificity of the SETD1B-related DNAm signature</title>
<p id="Par45">Whole blood DNA samples were collected from 502 patients with various neurodevelopmental syndromes. To compare the methylation values of our cohort with these additional samples, we performed re-normalization, according to the Illumina normalization method, with background correction using the “minfi” R-package. To select significant differentially methylated <italic>SETD1B</italic>-related CpGs, we used similar filtering steps for these in the <italic>SETD1B</italic>-related group analysis namely, a corrected <italic>P</italic> value less than 0.05 and an effect size of at least 10% difference. Correlated probes with <italic>r</italic><sup>2</sup> higher than 0.8 were removed from this analysis. Multidimensional scaling (MDS) was used to examine the DNA methylation profiles. All samples used in this analysis and the details of the method were fully described by Aref-Eshghi et al. [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. The list of 502 samples used in this specific analysis is listed in Additional file <xref ref-type="media" rid="MOESM5">5</xref>: Table S5.</p>
</sec>
<sec id="Sec21">
<title>Identification of differentially methylated regions</title>
<p id="Par46">To identify the DMRs between patient and control groups, a “bumphunter” R-package was used. The design model was corrected for age, gender, batch, and cell distribution.</p>
<p id="Par47">The <italic>P</italic> value for each region was calculated and multiple testing applied according to the family-wise error rate. The significant DMRs were selected based on the two filter steps: (i) Fwer &lt; 0.05 and (ii) at least three differentially methylated CpGs within the region (L &gt; 2).</p>
</sec>
<sec id="Sec22">
<title>ORA—WEB-based Gene Set Analysis Toolkit</title>
<p id="Par48">ORA were carried out for the first and unique gene symbol annotated to the CpGs identified during group analysis (according to the Infinium MethylationEPIC v1.0 B4 Manifest File). Basic parameters were as follows: organism–human, method–ORA, functional database–gene ontology (biological process and molecular function), and reference set for enrichment analysis–genome protein-coding. Advanced parameters were as follows: minimum number of genes for a category–5, maximum number of genes for category–2000, multiple test adjustment–Benjamini-Hochberg (BH), significant level–top 10, number of categories expected from set cover–10, number of categories visualized in the report–40, and color in DAG–continuous.</p>
</sec>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary information</title>
<sec id="Sec23">
<p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13148_2019_749_MOESM1_ESM.xlsx"><caption><p><bold>Additional file 1: Table S1.</bold> The estimation of the cell types distribution and the calculation of <italic>P</italic>-values of the cell types distribution.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13148_2019_749_MOESM2_ESM.xlsx"><caption><p><bold>Additional file 2: Table S2.</bold> Significant differentially methylated CpGs identified in the <italic>SETD1B</italic>-related group analysis.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13148_2019_749_MOESM3_ESM.xlsx"><caption><p><bold>Additional file 3: Table S3</bold>. Significant differentially methylated CpGs identified in the <italic>KDM2B</italic>-related group analysis.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM4"><media xlink:href="13148_2019_749_MOESM4_ESM.xlsx"><caption><p><bold>Additional file 4: Table S4.</bold> Cohort details.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM5"><media xlink:href="13148_2019_749_MOESM5_ESM.xlsx"><caption><p><bold>Additional file 5: Table S5.</bold> The list of 502 samples used in the examination of the specificity of the <italic>SETD1B</italic>-related DNAm signature.</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM6"><media xlink:href="13148_2019_749_MOESM6_ESM.xlsx"><caption><p><bold>Additional file 6: Table S6.</bold> Contains adjusted P-values for M values and empirical <italic>p</italic>-values for 3340 significant differentially methylated CpGs calculated in the <italic>SETD1B</italic>-related group analysis and permutation analysis, respectively.</p></caption></media></supplementary-material>
</p>
</sec>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>BWS</term>
<def>
<p id="Par2">Beckwith Wiedemann syndrome</p>
</def>
</def-item>
<def-item>
<term>DHS</term>
<def>
<p id="Par3">DNase I hypersensitivity site</p>
</def>
</def-item>
<def-item>
<term>DMR</term>
<def>
<p id="Par4">Differentially methylated region</p>
</def>
</def-item>
<def-item>
<term>Fwer</term>
<def>
<p id="Par5">Family-wise error rate</p>
</def>
</def-item>
<def-item>
<term>ID</term>
<def>
<p id="Par6">Intellectual disability</p>
</def>
</def-item>
<def-item>
<term>JME</term>
<def>
<p id="Par7">Juvenile myoclonic epilepsy</p>
</def>
</def-item>
<def-item>
<term>MAF</term>
<def>
<p id="Par8">Minor allele frequency</p>
</def>
</def-item>
<def-item>
<term>ORA</term>
<def>
<p id="Par9">Over-representation analysis</p>
</def>
</def-item>
<def-item>
<term>PCA</term>
<def>
<p id="Par10">Principal component analysis</p>
</def>
</def-item>
<def-item>
<term>QC</term>
<def>
<p id="Par11">Quality control</p>
</def>
</def-item>
<def-item>
<term>RDMR</term>
<def>
<p id="Par12">Reprogramming Differentially Methylated Regions</p>
</def>
</def-item>
<def-item>
<term>VUS</term>
<def>
<p id="Par13">Variant of uncertain significance</p>
</def>
</def-item>
<def-item>
<term>WES</term>
<def>
<p id="Par14">Whole-exome sequencing</p>
</def>
</def-item>
</def-list>
</glossary>
<fn-group>
<fn>
<p>
<bold>Publisher’s Note</bold>
</p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</fn>
<fn>
<p>M. Alders and M. M. A. M. Mannens contributed equally to this work.</p>
</fn>
<fn>
<p>This person has passed away.</p>
</fn>
</fn-group>
<sec>
<title>Supplementary information</title>
<p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s13148-019-0749-3.</p>
</sec>
<ack>
<title>Acknowledgements</title>
<p>We would like to thank the physicians and genetic counselors for their help with participant recruitment.</p>
<sec id="FPar4">
<title>Additional information</title>
<p id="Par60"> Contains additional information about (1) Quality control, (2) pre- processing data and statistical methods, (3) estimation of the cell type distribution, (4) statistical model, (5) verification of the results, (6) and the flow diagram of analysis.</p>
</sec>
</ack>
<notes notes-type="author-contribution">
<title>Authors’ contributions</title>
<p>MA, IMK, and MMAM designed the project. MA, SMM, KB, AC, AJE, TF, HI, MJ, H-GK, AL, SMEL, GL, IM, SM, NM, RR, ER-S,YQ. HS, DAS, and IMK contributed to the sample collection. SSM, DAS, H-GK, SD, SL, HS, NM, GL, RR, and NSS contributed to the clinical assessment of participants. IMK, MA, PH, BS, and EAE designed the statistical analysis. IMK, AV, BS, and EAE performed the statistical analysis. KL and IMK performed the laboratory experiments. IMK, MA, and BS wrote the manuscript. MMAM contributed to the manuscript revision. All authors reviewed the final version of the manuscript. All authors read and approved the final manuscript.</p>
</notes>
<notes notes-type="funding-information">
<title>Funding</title>
<p>The funding was obtained from the Catalan Government PERIS program (SLT002/16/00310) and the Techgene project from the FP7 framework (ID: 223143).</p>
</notes>
<notes notes-type="data-availability">
<title>Availability of data and materials</title>
<p>All HumanMethylation450 data are available on request.</p>
</notes>
<notes>
<title>Ethics approval and consent to participate</title>
<p id="Par49">METC waived (anonymous study, further study in line with a clinical question).</p>
</notes>
<notes>
<title>Consent for publication</title>
<p id="Par50">Not applicable</p>
</notes>
<notes notes-type="COI-statement">
<title>Competing interests</title>
<p id="Par51">The authors declare that they have no competing interests.</p>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baple</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Palmer</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hennekam</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>A microdeletion at 12q24.31 can mimic beckwith-wiedemann syndrome neonatally</article-title>
<source/>Mol Syndromol
          <year>2010</year>
<volume>1</volume>
<issue>1</issue>
<fpage>42</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="doi">10.1159/000275671</pub-id>
<pub-id pub-id-type="pmid">20648245</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chouery</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Choucair</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Abou Ghoch</surname>
<given-names>J</given-names>
</name>
<name>
<surname>El Sabbagh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corbani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Megarbane</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Report on a patient with a 12q24.31 microdeletion inherited from an insulin-dependent diabetes mellitus father</article-title>
<source/>Mol Syndromol
          <year>2013</year>
<volume>4</volume>
<issue>3</issue>
<fpage>136</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="pmid">23653585</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palumbo</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Palumbo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Delvecchio</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Palladino</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Stallone</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Crisetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zelante</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Carella</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Microdeletion of 12q24.31: report of a girl with intellectual disability, stereotypies, seizures and facial dysmorphisms</article-title>
<source/>Am J Med Genet A
          <year>2015</year>
<volume>167A</volume>
<issue>2</issue>
<fpage>438</fpage>
<lpage>444</lpage>
<pub-id pub-id-type="doi">10.1002/ajmg.a.36872</pub-id>
<pub-id pub-id-type="pmid">25428890</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tyson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hrynchak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lopez-Rangel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hildebrand</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fawcett</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kasmara</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Calli</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Harvard</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical application of 2.7M Cytogenetics array for CNV detection in subjects with idiopathic autism and/or intellectual disability</article-title>
<source/>Clin Genet
          <year>2013</year>
<volume>83</volume>
<issue>2</issue>
<fpage>145</fpage>
<lpage>154</lpage>
<pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01860.x</pub-id>
<pub-id pub-id-type="pmid">22369279</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Labonne</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Iwase</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Layman</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>HG</given-names>
</name>
</person-group>
<article-title>An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability</article-title>
<source/>Hum Genet
          <year>2016</year>
<volume>135</volume>
<issue>7</issue>
<fpage>757</fpage>
<lpage>771</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-016-1668-4</pub-id>
<pub-id pub-id-type="pmid">27106595</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barski</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cuddapah</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>TY</given-names>
</name>
<name>
<surname>Schones</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Chepelev</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>High-resolution profiling of histone methylations in the human genome</article-title>
<source/>Cell
          <year>2007</year>
<volume>129</volume>
<issue>4</issue>
<fpage>823</fpage>
<lpage>837</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2007.05.009</pub-id>
<pub-id pub-id-type="pmid">17512414</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janzer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stamm</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buettner</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kirfel</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>The H3K4me3 histone demethylase Fbxl10 is a regulator of chemokine expression, cellular morphology, and the metabolome of fibroblasts</article-title>
<source/>J Biol Chem
          <year>2012</year>
<volume>287</volume>
<issue>37</issue>
<fpage>30984</fpage>
<lpage>30992</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M112.341040</pub-id>
<pub-id pub-id-type="pmid">22825849</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hiraide</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakashima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Fukuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sugie</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Aoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaname</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakabayashi</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>De novo variants in SETD1B are associated with intellectual disability, epilepsy and autism</article-title>
<source/>Hum Genet
          <year>2018</year>
<volume>137</volume>
<issue>1</issue>
<fpage>95</fpage>
<lpage>104</lpage>
<pub-id pub-id-type="doi">10.1007/s00439-017-1863-y</pub-id>
<pub-id pub-id-type="pmid">29322246</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Den</surname>
<given-names>Kouhei</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>Mitsuhiro</given-names>
</name>
<name>
<surname>Yamaguchi</surname>
<given-names>Tokito</given-names>
</name>
<name>
<surname>Miyatake</surname>
<given-names>Satoko</given-names>
</name>
<name>
<surname>Takata</surname>
<given-names>Atsushi</given-names>
</name>
<name>
<surname>Mizuguchi</surname>
<given-names>Takeshi</given-names>
</name>
<name>
<surname>Miyake</surname>
<given-names>Noriko</given-names>
</name>
<name>
<surname>Mitsuhashi</surname>
<given-names>Satomi</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>Naomichi</given-names>
</name>
</person-group>
<article-title>A novel de novo frameshift variant in SETD1B causes epilepsy</article-title>
<source/>Journal of Human Genetics
          <year>2019</year>
<volume>64</volume>
<issue>8</issue>
<fpage>821</fpage>
<lpage>827</lpage>
<pub-id pub-id-type="doi">10.1038/s10038-019-0617-1</pub-id>
<pub-id pub-id-type="pmid">31110234</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cedar</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bergman</surname>
<given-names>Y</given-names>
</name>
</person-group>
<article-title>Linking DNA methylation and histone modification: patterns and paradigms</article-title>
<source/>Nat Rev Genet
          <year>2009</year>
<volume>10</volume>
<issue>5</issue>
<fpage>295</fpage>
<lpage>304</lpage>
<pub-id pub-id-type="doi">10.1038/nrg2540</pub-id>
<pub-id pub-id-type="pmid">19308066</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimshony</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Keshet</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Bustin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cedar</surname>
<given-names>H</given-names>
</name>
</person-group>
<article-title>The role of DNA methylation in setting up chromatin structure during development</article-title>
<source/>Nat Genet
          <year>2003</year>
<volume>34</volume>
<issue>2</issue>
<fpage>187</fpage>
<lpage>192</lpage>
<pub-id pub-id-type="doi">10.1038/ng1158</pub-id>
<pub-id pub-id-type="pmid">12740577</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aref-Eshghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Schenkel</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ainsworth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pare</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Rodenhiser</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sadikovic</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>The defining DNA methylation signature of Kabuki syndrome enables functional assessment of genetic variants of unknown clinical significance</article-title>
<source/>Epigenetics
          <year>2017</year>
<volume>12</volume>
<issue>11</issue>
<fpage>923</fpage>
<lpage>933</lpage>
<pub-id pub-id-type="doi">10.1080/15592294.2017.1381807</pub-id>
<pub-id pub-id-type="pmid">28933623</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choufani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cytrynbaum</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>BH</given-names>
</name>
<name>
<surname>Turinsky</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Grafodatskaya</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YA</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Butcher</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>MT</given-names>
</name>
<etal></etal>
</person-group>
<article-title>NSD1 mutations generate a genome-wide DNA methylation signature</article-title>
<source/>Nat Commun
          <year>2015</year>
<volume>6</volume>
<fpage>10207</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms10207</pub-id>
<pub-id pub-id-type="pmid">26690673</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobreira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Schiettecatte</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Valle</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hamosh</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>GeneMatcher: a matching tool for connecting investigators with an interest in the same gene</article-title>
<source/>Hum Mutat
          <year>2015</year>
<volume>36</volume>
<issue>10</issue>
<fpage>928</fpage>
<lpage>930</lpage>
<pub-id pub-id-type="doi">10.1002/humu.22844</pub-id>
<pub-id pub-id-type="pmid">26220891</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krzyzewska</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Alders</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maas</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Bliek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Venema</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Henneman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rezwan</surname>
<given-names>FI</given-names>
</name>
<name>
<surname>Lip</surname>
<given-names>KVD</given-names>
</name>
<name>
<surname>Mul</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Mackay</surname>
<given-names>DJG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genome-wide methylation profiling of Beckwith-Wiedemann syndrome patients without molecular confirmation after routine diagnostics</article-title>
<source/>Clin Epigenetics
          <year>2019</year>
<volume>11</volume>
<issue>1</issue>
<fpage>53</fpage>
<pub-id pub-id-type="doi">10.1186/s13148-019-0649-6</pub-id>
<pub-id pub-id-type="pmid">30898153</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aref-Eshghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rodenhiser</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Schenkel</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>HX</given-names>
</name>
<name>
<surname>Skinner</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ainsworth</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pare</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hood</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Bulman</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Kernohan</surname>
<given-names>KD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genomic DNA methylation signatures enable concurrent diagnosis and clinical genetic variant classification in neurodevelopmental syndromes</article-title>
<source/>Am J Hum Genet
          <year>2018</year>
<volume>102</volume>
<issue>1</issue>
<fpage>156</fpage>
<lpage>174</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.12.008</pub-id>
<pub-id pub-id-type="pmid">29304373</pub-id>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aref-Eshghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bend</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Colaiacovo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Caudle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Napier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brick</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brady</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Carere</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Levy</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diagnostic utility of genome-wide DNA methylation testing in genetically unsolved individuals with suspected hereditary conditions</article-title>
<source/>Am J Hum Genet
          <year>2019</year>
<volume>104</volume>
<issue>4</issue>
<fpage>685</fpage>
<lpage>700</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2019.03.008</pub-id>
<pub-id pub-id-type="pmid">30929737</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sobreira</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Brucato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ladd-Acosta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ongaco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Romm</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doheny</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Mingroni-Netto</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Bertola</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>CA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Patients with a Kabuki syndrome phenotype demonstrate DNA methylation abnormalities</article-title>
<source/>Eur J Hum Genet
          <year>2017</year>
<volume>25</volume>
<issue>12</issue>
<fpage>1335</fpage>
<lpage>1344</lpage>
<pub-id pub-id-type="doi">10.1038/s41431-017-0023-0</pub-id>
<pub-id pub-id-type="pmid">29255178</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butcher</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Cytrynbaum</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Turinsky</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Siu</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Inbar-Feigenberg</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mendoza-Londono</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chitayat</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Machado</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Caluseriu</surname>
<given-names>O</given-names>
</name>
<etal></etal>
</person-group>
<article-title>CHARGE and Kabuki syndromes: gene-specific DNA methylation signatures identify epigenetic mechanisms linking these clinically overlapping conditions</article-title>
<source/>Am J Hum Genet
          <year>2017</year>
<volume>100</volume>
<issue>5</issue>
<fpage>773</fpage>
<lpage>788</lpage>
<pub-id pub-id-type="doi">10.1016/j.ajhg.2017.04.004</pub-id>
<pub-id pub-id-type="pmid">28475860</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aref-Eshghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bend</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Hood</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Schenkel</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Carere</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Chakrabarti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Nagamani</surname>
<given-names>SCS</given-names>
</name>
<name>
<surname>Cheung</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Campeau</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>C</given-names>
</name>
<etal></etal>
</person-group>
<article-title>BAFopathies’ DNA methylation epi-signatures demonstrate diagnostic utility and functional continuum of Coffin-Siris and Nicolaides-Baraitser syndromes</article-title>
<source/>Nat Commun
          <year>2018</year>
<volume>9</volume>
<issue>1</issue>
<fpage>4885</fpage>
<pub-id pub-id-type="doi">10.1038/s41467-018-07193-y</pub-id>
<pub-id pub-id-type="pmid">30459321</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kent</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Sugnet</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Furey</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Roskin</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Pringle</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Zahler</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Haussler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The human genome browser at UCSC</article-title>
<source/>Genome Res
          <year>2002</year>
<volume>12</volume>
<issue>6</issue>
<fpage>996</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="doi">10.1101/gr.229102</pub-id>
<pub-id pub-id-type="pmid">12045153</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vasaikar</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Greer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit</article-title>
<source/>Nucleic Acids Res
          <year>2017</year>
<volume>45</volume>
<issue>W1</issue>
<fpage>W130</fpage>
<lpage>W137</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkx356</pub-id>
<pub-id pub-id-type="pmid">28472511</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<mixed-citation publication-type="other">Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, Collins RL, Laricchia KM, Ganna A, Birnbaum DP et al. Variation across 141,456 human exomes and genomes reveals the spectrum of loss-of-function intolerance across human protein-coding genes. bioRxiv. 2019:531210.</mixed-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kijima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mizuta</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Histone H1 quantity determines the efficiencies of apoptotic DNA fragmentation and chromatin condensation</article-title>
<source/>Biomed Res Tokyo
          <year>2019</year>
<volume>40</volume>
<issue>1</issue>
<fpage>51</fpage>
<lpage>56</lpage>
<pub-id pub-id-type="doi">10.2220/biomedres.40.51</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Turner</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wilkins</surname>
<given-names>OG</given-names>
</name>
<name>
<surname>Cato</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Travers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Stott</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Highly disordered histone H1-DNA model complexes and their condensates</article-title>
<source/>P Natl Acad Sci USA
          <year>2018</year>
<volume>115</volume>
<issue>47</issue>
<fpage>11964</fpage>
<lpage>11969</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1805943115</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pathak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>WCL</given-names>
</name>
<name>
<surname>Greenberg</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>DNA methylation of the BRD2 promoter is associated with juvenile myoclonic epilepsy in Caucasians</article-title>
<source/>Epilepsia
          <year>2018</year>
<volume>59</volume>
<issue>5</issue>
<fpage>1011</fpage>
<lpage>1019</lpage>
<pub-id pub-id-type="doi">10.1111/epi.14058</pub-id>
<pub-id pub-id-type="pmid">29608786</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<mixed-citation publication-type="other">Schulz H, Ruppert AK, Zara F, Madia F, Iacomino M, Vari MS, Balagura G, Minetti C, Striano P, Blanche A et al. No evidence for a BRD2 promoter hypermethylation inblood leukocytes of Europeans with juvenile myoclonic epilepsy. Epilepsia. 2019;60(5):E31–E36.</mixed-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cavalleri</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Walley</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Soranzo</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mulley</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doherty</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Kapoor</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Depondt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lynch</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Scheffer</surname>
<given-names>IE</given-names>
</name>
<name>
<surname>Heils</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A multicenter study of BRD2 as a risk factor for juvenile myoclonic epilepsy</article-title>
<source/>Epilepsia
          <year>2007</year>
<volume>48</volume>
<issue>4</issue>
<fpage>706</fpage>
<lpage>712</lpage>
<pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.00977.x</pub-id>
<pub-id pub-id-type="pmid">17437413</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Testoni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bartolone</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Patrignani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bruggmann</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lichtner</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tetens</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gentile</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Drogemuller</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>KDM2B is implicated in bovine lethal multi-organic developmental dysplasia</article-title>
<source/>PLoS One
          <year>2012</year>
<volume>7</volume>
<issue>9</issue>
<fpage>e45634</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0045634</pub-id>
<pub-id pub-id-type="pmid">23029151</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brioude</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kalish</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Mussa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bliek</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ferrero</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Boonen</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bertoletti</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expert consensus document: clinical and molecular diagnosis, screening and management of Beckwith-Wiedemann syndrome: an international consensus statement</article-title>
<source/>Nat Rev Endocrinol
          <year>2018</year>
<volume>14</volume>
<issue>4</issue>
<fpage>229</fpage>
<lpage>249</lpage>
<pub-id pub-id-type="doi">10.1038/nrendo.2017.166</pub-id>
<pub-id pub-id-type="pmid">29377879</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Klose</surname>
<given-names>RJ</given-names>
</name>
</person-group>
<article-title>Understanding the relationship between DNA methylation and histone lysine methylation</article-title>
<source/>Biochim Biophys Acta
          <year>2014</year>
<volume>1839</volume>
<issue>12</issue>
<fpage>1362</fpage>
<lpage>1372</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.02.007</pub-id>
<pub-id pub-id-type="pmid">24560929</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aryee</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>AE</given-names>
</name>
<name>
<surname>Corrada-Bravo</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ladd-Acosta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Feinberg</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Irizarry</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays</article-title>
<source/>Bioinformatics
          <year>2014</year>
<volume>30</volume>
<issue>10</issue>
<fpage>1363</fpage>
<lpage>1369</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btu049</pub-id>
<pub-id pub-id-type="pmid">24478339</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salas</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Koestler</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Butler</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Wiencke</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Kelsey</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>BC</given-names>
</name>
</person-group>
<article-title>An optimized library for reference-based deconvolution of whole-blood biospecimens assayed using the Illumina HumanMethylationEPIC BeadArray</article-title>
<source/>Genome Biol
          <year>2018</year>
<volume>19</volume>
<issue>1</issue>
<fpage>64</fpage>
<pub-id pub-id-type="doi">10.1186/s13059-018-1448-7</pub-id>
<pub-id pub-id-type="pmid">29843789</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>